Skip to content
DataLookout
Menu

NCT05053971

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 99 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Site details revised at 3 of 3 sites
  2. Notable Eligibility criteria shortened, about 12 words Show 4 more changesShow less
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description revised
    • Site contacts updated at 1 of 3 sites
    • Publications: details revised at 1 of 1 entry
  3. Notable Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027v96
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD) (Phase Ib)
Timeframe: Up to 28 days
Recommended phase 2 dose (RP2D) (Phase Ib)
Timeframe: Up to 28 days
Objective response rate (ORR) (Phase II)
Timeframe: Up to 4 weeks post intervention

Secondary (4)

Response rate (RR) in patients with advanced/progressive pancreatic cancer (Phase II)
Duration of response
Overall survival
Progression free survival

Arms and interventions

Treatment (entinostat, ZEN003694)Experimental

PHASE I RUN-IN PERIOD (DAILY DOSING) (NO LONGER USED PER AMENDMENT DATED JUNE 12, 2025): Patients receive ZEN003694 PO QD during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy. PHASE I \& II COMBINATION TREATMENT (DAILY DOSING) (NO LONGER USED PER AMENDMENT DATED JUNE 12, 2025): Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14. PHASE I and PHASE II (INTERMITTENT DOSING): Patients receive entinostat PO on days 1, 8, 15, and 22 of each cycle and ZEN003694 PO QD on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT throughout the study.

Drugs: BET Bromodomain Inhibitor ZEN-3694, Entinostat

Procedures: Computed Tomography, Core Biopsy

Sites

3 sites in 1 country